Real-World Data Support Use of rpFVIII for Acquired Hemophilia A - HCPLive
A real-world report supports recombinant porcine factor VIII (rpFVIII) for treating bleeding in adults with acquired hemophilia A, with no new safety concerns. The study aligns with Phase 2/3 trial results, showing no hypersensitivity or thromboembolic events. rpFVIII is recommended as first-line treatment in EU, UK, and US guidelines, with 74% of initial bleeding events resolved after treatment.
Reference News
A real-world report supports recombinant porcine factor VIII (rpFVIII) for treating bleeding in adults with acquired hemophilia A, with no new safety concerns. The study aligns with Phase 2/3 trial results, showing no hypersensitivity or thromboembolic events. rpFVIII is recommended as first-line treatment in EU, UK, and US guidelines, with 74% of initial bleeding events resolved after treatment.